Therapeutic Area
-
Acute Myeloid Leukemia (AML) -The Changing Landscape of Treatment in AML, Executive Deck 2020
$7,500.00 – $15,450.00Select optionsAcute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 470 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results (~ 96 trial’s results) from ASH 2019, ASCO 2020 and EHA 2020. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.
-
Allergic Conjuctivitis (AC) | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00Select optionsThe Allergic Conjuctivitis (AC) report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Hemophilia A Gene Therapy- Key opinion leaders (KOLs) Insight- An Executive Report 2020
$6,250.00 – $16,750.00Select optionsHemophilia A Gene Therapy- Key opinion leaders (KOLs) Insight- An Executive Report 2020 Deck provides a competitive advantage towards understanding the current gene therapy challenges, safety and efficacy concerns, hemophilia A gene therapy market uptake, Gene therapy competition, Hem A gene therapy re-dosing, Patients switching to gene therapy from hemlibra and factor replacement therapies and other critical key intelligent questions through 14 in-depth interviews with leading US and European KOLs.
-
High grade intraepithelial lesion (HSIL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00 Select options -
Narcolepsy | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00Select optionsThe Narcolepsy report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
Neuroblastoma | Landscape & Forecast | Competitive Landscape & Forecast, 2020-2030
$5,250.00 – $15,750.00Select optionsThe Neuroblastoma report provides the detailed overview of the disease and exhaustive understanding of historical and forecasted epidemiology. It highlights the prevailing treatment patterns, potential upcoming drugs and also identifies better of the market opportunities by providing the historical and forecasted market revenue, sales trends, and drug uptake during the study period from 2019-2030.
-
T-Cell Receptor (TCR) Therapy- Executive Report 2020
$3,000.00 – $9,000.00Select optionsA Comprehensive Review on TCR Cell Therapy by Pipeline Analysis, Emerging Players having Innovative Portfolio, Commercial Assessment of Developmental Activities, Therapeutic Portfolio Assessment, Objective Assessment of Unmet Needs, Future Perspectives, and Technological Advancements to make informed R&D related decisions, modify therapeutic portfolio strategies, identify growth opportunities, strengthen or expand business by gaining extensive view.
-
TIGIT Inhibitors – Market Opportunity, Pipeline & Competitive Intelligence 2020
$3,950.00 – $11,850.00Select optionsThis TIGIT report covers the TIGIT market opportunity providing Key Competitive Analysis, 15+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc), Licensing and Agreements, Business Agreement, business partner, Clinical Agreement, 2020 Earnings call update, Market launch preparation, Marketing Strategy, Future agenda and Upcoming events.